The FDA has authorized 20 ZYN nicotine pouch products from Philip Morris International (NYSE: PM), marking the first approval of its kind. After a thorough review, the FDA confirmed these products ...

While technology stocks get a lot of attention from the media, there are a lot of attractive options in the consumer goods ...

This approval marks a significant milestone as ZYN is now one of the few flavored ... regulatory trends and consumer preferences. The price objective of $143 reflects a premium valuation ...

The FDA’s decision supports Philip Morris’s ability to keep ZYN on the U.S. market ... with a target price of $145. In another report released today, Barclays also assigned a Buy rating ...

Below is the list of Zyn products that were granted marketing ... which implies a dividend yield of 4.51% at current stock prices. The yield on the consumer staples ETF is 2.83%, and the implied ...

Zyn, an alternative to traditional chewing tobacco ... poised to be sworn in for his second presidency. Energycategory Oil prices little changed; markets await Trump move on Russian export curbs ...

Jana Hughes of Seward introduced a bill (LB125) that would tax "alternative nicotine products" — such as the newly popular ZYN nicotine pouches — at a rate of 20% of their wholesale price.

A P/E of 19x would, in our view, more accurately price in the steady growth of IQOS availability in the United States and Zyn smoke-free nicotine pouches. PM has committed to being 66% smoke-free ...

After that pullback, the stock now offers a dividend yield of 4.5% and trades at a reasonable price-to-earnings ratio of 19. With momentum building in products like iQOS and Zyn, the stock looks ...